Emyria (ASX:EMD) - Managing Director, Michael Winlo
Managing Director, Michael Winlo
Source: Emyria
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Emyria (EMD) appoints Sixty Two Capital as its corporate advisor to support its next phase of growth
  • Under the appointment, Sixty Two Capital will provide a range of corporate advisory services to Emyria
  • For these services, Emyria will pay Sixty Two a monthly retainer of $10,000 per month over the next year and issue a total of six million performance advisory options
  • Emyria’s Managing Director, Michael Winlo, said Sixty Two have been strong supporters of Emyria ever since their first corner-stoned placement in December 2020.
  • On the market, Emyria is down 1.37 per cent and trading at 36 cents per share

Emyria (EMD) has appointed Sixty Two Capital as its corporate advisor to support its next phase of growth.

Sixty Two Capital is a corporate advisory, brokerage and investment group specialising in supporting the growth of emerging companies listed on the ASX.

Under the appointment, Sixty Two Capital will provide a range of corporate advisory services to Emyria for capital markets requirements, investor relations and the identification of additional, value-creating strategic opportunities.

For these services, Emyria will pay Sixty Two a monthly retainer of $10,000 per month over the next year and issue a total of six million performance advisory options with an exercise price of 55 cents each, expiring two years from the date of issue.

Emyria’s Managing Director, Michael Winlo, said Sixty Two have been strong supporters of Emyria ever since their first corner-stoned placement in December 2020.

“Sixty Two Capital has a track record of supporting high growth client companies over the long-term,” Dr Winlo said.

“We are delighted to have their support as Emyria advances our major programs in the new year.”

Sixty Two Capital’s Director, Sufian Ahmad, said Sixty Two Capital is pleased to help Emyria in its next phase of growth.

“We believe that Emyria’s unique data-backed drug development platform has potential to bring new treatments to major patient populations globally, and in doing so, also generate significant returns for shareholders,” he said.

On the market, Emyria was down 1.37 per cent and is trading at 36 cents per share at 12:57 pm AEDT.

EMD by the numbers
More From The Market Herald
Limeade (ASX:LME) - CEO, Henry Albrecht

" Limeade (ASX:LME) maintains FY21 financial guidance in quarterly report

Limeade (ASX:LME) has maintained its FY21 revenue guidance of $50 million to $53 million, but posted…
Sihayo Gold (ASX:SIH) - Executive Chairman, Colin Moorhead

" Sihayo Gold (ASX:SIH) secures further interim funding

Sihayo Gold (ASX:SIH) has secured interim funding from its shareholder, PT Saratoga Investama Sedaya Tbk.

" Alchemy Resources (ASX:ALY) commences aircore drilling at Karonie

Aircore drilling is underway at Alchemy Resources' (ASX:ALY) Karonie gold project 110 kilometres east of Kalgoorlie,…
Little Green Pharma (ASX:LGP) - Managing Director, Fleta Solomon

" Little Green Pharma (ASX:LGP) seeks to expand to Greece

Little Green Pharma (ASX:LGP) seeks to expand to Greece